DOLE
20.12.2022 17:17:38 CET | Business Wire | Press release
Dole plc (NYSE: DOLE) announced today the release of its first sustainability report since the 2021 merger of Total Produce plc and Dole Food Company. Building on its historical achievements, this report sets out the organization’s refreshed sustainability framework and offers a new set of environmental, social and governance (ESG) goals through 2030.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221220005564/en/
The Dole Way, Dole’s sustainability framework, focuses on robust governance and three core pillars—For Nature, For People and For Food—covering environmental, ethical and social and nutrition related issues. These three pillars incorporate key areas identified as being most material to the impact of our business’ operations.
- For Nature: By committing to the Science Based Target Initiative, Dole plc places climate action at the forefront of its priorities along with water stewardship, biodiversity, waste management and packaging reduction and innovation.
- For People: Directly employing 38,500 people globally while partnering with third party growers worldwide, Dole is committed to being an employer of choice, supporting local communities and protecting human rights across its supply chains.
- For Food: Dole is committing to promoting healthy nutrition and improving access to fresh produce through partnerships and donations.
“Dole has built market-leading positions across a wide range of fresh fruit and vegetable segments by incorporating sustainability into their growth models,” stated Rory Byrne, Dole plc Chief Executive Officer. “As our climate is changing, we are focused on identifying the related risks, adapting to the effects on our operations and minimizing our own impacts. We also recognize and relish the special role we can play in improving people’s lives and the contribution Dole can make to promoting good health and wellbeing.”
The report also lays the foundation for the promotion of regenerative farming practices across Dole’s own operations as well as on associated farms which will support the business’ ambitious climate goals.
Highlights of the report include Dole plc’s:
- First global carbon footprint collection including measuring and managing scope 1, scope 2 and scope 3 emissions resulting in a reduction of 4% in Scope 1 and 2 emissions (2021 over 2020)
- Investment in Renewal Energy with two 2.8 megawatt wind turbines in Dole Fresh Vegetables in Soledad, California and installed new solar panel system at Belfast, Ireland site with a capacity of 120 kWp
- Recognition by American-Costa Rican Chamber of Commerce (AmCham) of Dole affiliate, Standard Fruit Company de Costa Rica S.A., for their innovative project "De la Mano con Dole." The project positively impacts the social development of employees and their families using the Business Multidimensional Poverty Index (bMPI) methodology which measures poverty beyond only per capita income - to include access to health, education, housing, work, social protection and 16 other key indicators.
Xavier Roussel, Dole plc’s Chief Marketing and Sustainability officer, stated, “Although fresh produce has a low environmental footprint in comparison to other food sources, there is still much to do to further decrease our impacts and adapt to the effects of climate change. We are addressing those challenges for the long term with likeminded partners along the supply chain. Our vertically integrated business model allows us to research much in our own operations before expanding to our associated farmers which is instrumental to lead change in the industry.”
Adding, “Caring for our most important resources: our people, the nature around us and the food we deliver to the world is our way to contribute to society and will set us up for continued success.”
To view the full Dole plc 2022 Corporate Responsibility & Sustainability Report click here or visit www.doleplc.com.
About Dole plc
A global leader in fresh produce, Dole Plc grows, markets, and distributes an extensive variety of fresh fruits and vegetables sourced locally and from around the world. Dedicated and passionate in exceeding our customers’ requirements in over 75 countries, our goal is to make the world a healthier and a more sustainable place. For more information, please visit www.doleplc.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005564/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
